Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 301,370
  • Shares Outstanding, K 68,806
  • Annual Sales, $ 20,760 K
  • Annual Income, $ -132,490 K
  • 60-Month Beta 3.11
  • Price/Sales 14.52
  • Price/Cash Flow N/A
  • Price/Book 1.17
Trade CCCC with:

Options Overview Details

View History
  • Implied Volatility 93.70% ( +11.44%)
  • Historical Volatility 56.17%
  • IV Percentile 31%
  • IV Rank 19.48%
  • IV High 401.71% on 02/05/24
  • IV Low 19.20% on 05/29/24
  • Put/Call Vol Ratio 0.95
  • Today's Volume 148
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 12,414
  • Open Int (30-Day) 12,200

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -0.46
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +49.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.08 +1.47%
on 06/17/24
5.86 -29.35%
on 05/22/24
-1.54 (-27.11%)
since 05/17/24
3-Month
4.08 +1.47%
on 06/17/24
9.19 -54.93%
on 03/21/24
-4.79 (-53.64%)
since 03/15/24
52-Week
1.06 +290.57%
on 12/06/23
11.88 -65.15%
on 03/04/24
+0.77 (+22.85%)
since 06/16/23

Most Recent Stories

More News
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...

ONCY : 1.0100 (-0.98%)
TCRX : 7.44 (-11.43%)
BMY : 40.97 (-0.56%)
PDSB : 2.67 (-4.13%)
CCCC : 4.14 (-5.48%)
ONC.TO : 1.39 (-0.71%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 1.0100 (-0.98%)
ONC.TO : 1.39 (-0.71%)
TCRX : 7.44 (-11.43%)
BMY : 40.97 (-0.56%)
PDSB : 2.67 (-4.13%)
CCCC : 4.14 (-5.48%)
Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. (CCCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

CCCC : 4.14 (-5.48%)
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

CCCC : 4.14 (-5.48%)
RAPT : 3.31 (-0.30%)
Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?

Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

FULC : 7.00 (-6.04%)
CCCC : 4.14 (-5.48%)
C4 Therapeutics, Inc. (CCCC) Dips More Than Broader Markets: What You Should Know

In the latest trading session, C4 Therapeutics, Inc. (CCCC) closed at $6.51, marking a -1.96% move from the previous day.

CCCC : 4.14 (-5.48%)
Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year?

Here is how AMN Healthcare Services (AMN) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

AMN : 53.89 (-2.57%)
CCCC : 4.14 (-5.48%)
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet

The consensus price target hints at a 227.3% upside potential for C4 Therapeutics, Inc. (CCCC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

CCCC : 4.14 (-5.48%)
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CCCC : 4.14 (-5.48%)
AFMD : 6.74 (-5.07%)
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

C4 Therapeutics, Inc. (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CCCC : 4.14 (-5.48%)
CLNN : 0.3736 (-2.48%)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 4.80
2nd Resistance Point 4.65
1st Resistance Point 4.39
Last Price 4.14
1st Support Level 3.98
2nd Support Level 3.83
3rd Support Level 3.57

See More

52-Week High 11.88
Fibonacci 61.8% 7.75
Fibonacci 50% 6.47
Fibonacci 38.2% 5.19
Last Price 4.14
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar